Louise A. Koopman

4.1k total citations · 2 hit papers
24 papers, 3.2k citations indexed

About

Louise A. Koopman is a scholar working on Immunology, Oncology and Epidemiology. According to data from OpenAlex, Louise A. Koopman has authored 24 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Immunology, 10 papers in Oncology and 6 papers in Epidemiology. Recurrent topics in Louise A. Koopman's work include Immune Cell Function and Interaction (8 papers), Reproductive System and Pregnancy (7 papers) and T-cell and B-cell Immunology (5 papers). Louise A. Koopman is often cited by papers focused on Immune Cell Function and Interaction (8 papers), Reproductive System and Pregnancy (7 papers) and T-cell and B-cell Immunology (5 papers). Louise A. Koopman collaborates with scholars based in United States, Netherlands and Denmark. Louise A. Koopman's co-authors include Jack L. Strominger, Jonathan E. Boyson, Jordan S. Orange, Basya Rybalov, Hernan D. Kopcow, Frederick Schatz, Jeff Settleman, Patricia Greninger, Nabeel Bardeesy and Daniel R. Rhodes and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and The Journal of Experimental Medicine.

In The Last Decade

Louise A. Koopman

24 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Human Decidual Natural Killer Cells Are a Unique NK Cell Subset with Immunomodulatory Potential

2003 696 citations Louise A. Koopman, Hernan D. Kopcow et al. The Journal of Experimental Medicine profile →
A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival

2009 630 citations Anurag Singh, Patricia Greninger et al. Cancer Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Louise A. Koopman United States	18	2.2k	765	752	539	500	24	3.2k
Antonella Ravaggi Italy	34	967 0.4×	783 1.0×	833 1.1×	490 0.9×	777 1.6×	104	3.3k
Mark S. Singer United States	22	1.6k 0.7×	1.7k 2.2×	393 0.5×	161 0.3×	190 0.4×	33	3.4k
Kwong-Yok Tsang United States	25	2.5k 1.1×	946 1.2×	1.8k 2.4×	182 0.3×	234 0.5×	45	3.3k
David W. Kindelberger United States	23	354 0.2×	777 1.0×	768 1.0×	1.1k 2.1×	2.3k 4.7×	38	3.6k
Lambert G. Poels Netherlands	26	453 0.2×	535 0.7×	213 0.3×	247 0.5×	451 0.9×	64	1.7k
Lena Ångman Switzerland	11	2.7k 1.3×	260 0.3×	581 0.8×	93 0.2×	246 0.5×	14	3.1k
Marja‐Liisa Huhtala Finland	21	384 0.2×	714 0.9×	393 0.5×	132 0.2×	247 0.5×	31	1.8k
Jo Hilgers Netherlands	30	672 0.3×	1.1k 1.5×	523 0.7×	53 0.1×	262 0.5×	76	2.3k
David B. Rosen United States	18	2.1k 1.0×	525 0.7×	436 0.6×	83 0.2×	47 0.1×	42	2.6k

Countries citing papers authored by Louise A. Koopman

Since Specialization

Citations

This map shows the geographic impact of Louise A. Koopman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Louise A. Koopman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Louise A. Koopman more than expected).

Fields of papers citing papers by Louise A. Koopman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Louise A. Koopman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Louise A. Koopman. The network helps show where Louise A. Koopman may publish in the future.

Co-authorship network of co-authors of Louise A. Koopman

This figure shows the co-authorship network connecting the top 25 collaborators of Louise A. Koopman. A scholar is included among the top collaborators of Louise A. Koopman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Louise A. Koopman. Louise A. Koopman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kemper, Kristel, Péter Boross, Mischa Houtkamp, et al.. (2022). Mechanistic and pharmacodynamic studies of DuoBody-CD3x5T4 in preclinical tumor models. Life Science Alliance. 5(11). e202201481–e202201481. 3 indexed citations

Singh, Anurag, Patricia Greninger, Daniel Rhodes, et al.. (2021). A gene expression signature associated with ‘‘K-Ras addiction’’ reveals regulators of EMT and tumor cell survival. Cancer Cell. 39(3). 441–442. 5 indexed citations

Koopman, Louise A., Mikkel G. Terp, Gijs G. Zom, et al.. (2019). Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer. JCI Insight. 4(21). 46 indexed citations

Gustafsson, Renata, Alexei V. Salnikov, Kathrin S. Zeller, et al.. (2018). Inhibition of integrin αVβ6 changes fibril thickness of stromal collagen in experimental carcinomas. Cell Communication and Signaling. 16(1). 36–36. 10 indexed citations

Boshuizen, Julia, Louise A. Koopman, Oscar Krijgsman, et al.. (2018). Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. Nature Medicine. 24(2). 203–212. 164 indexed citations

Koopman, Louise A., Maarten L. Janmaat, Kirstine Jacobsen, et al.. (2018). Abstract 832: An AXL-specific antibody-drug conjugate shows preclinical anti-tumor activity in non-small cell lung cancer, including EGFR-inhibitor resistant NSCLC. Cancer Research. 78(13_Supplement). 832–832. 9 indexed citations

Boshuizen, Julia, Louise A. Koopman, Esther C.W. Breij, et al.. (2017). Abstract 4591: Specific elimination of invasive and multidrug-resistant cancer cells by an antibody-drug conjugate targeting AXL. Cancer Research. 77(13_Supplement). 4591–4591. 1 indexed citations

Lockwood, Charles J., S. Joseph Huang, Chie‐Pein Chen, et al.. (2013). Decidual Cell Regulation of Natural Killer Cell–Recruiting Chemokines. American Journal Of Pathology. 183(3). 841–856. 66 indexed citations

Singh, Anurag, Patricia Greninger, Daniel R. Rhodes, et al.. (2009). A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival. Cancer Cell. 15(6). 489–500. 630 indexed citations breakdown →

10.

Keskin, Derin B., David Allan, Basya Rybalov, et al.. (2007). TGFβ promotes conversion of CD16 ⁺ peripheral blood NK cells into CD16 ⁻ NK cells with similarities to decidual NK cells. Proceedings of the National Academy of Sciences. 104(9). 3378–3383. 297 indexed citations

11.

Lockwood, Charles J., Graciela Krikun, Louise A. Koopman, et al.. (2006). Regulation of Monocyte Chemoattractant Protein-1 Expression by Tumor Necrosis Factor-α and Interleukin-1β in First Trimester Human Decidual Cells. American Journal Of Pathology. 168(2). 445–452. 103 indexed citations

12.

Lockwood, Charles J., Michael J. Paidas, Graciela Krikun, et al.. (2005). Inflammatory Cytokine and Thrombin Regulation of Interleukin-8 and Intercellular Adhesion Molecule-1 Expression in First Trimester Human Decidua. The Journal of Clinical Endocrinology & Metabolism. 90(8). 4710–4715. 20 indexed citations

13.

Koopman, Louise A., Hernan D. Kopcow, Basya Rybalov, et al.. (2003). Human Decidual Natural Killer Cells Are a Unique NK Cell Subset with Immunomodulatory Potential. The Journal of Experimental Medicine. 198(8). 1201–1212. 696 indexed citations breakdown →

14.

Orange, Jordan S., Marlys S. Fassett, Louise A. Koopman, Jonathan E. Boyson, & Jack L. Strominger. (2002). Viral evasion of natural killer cells. Nature Immunology. 3(11). 1006–1012. 155 indexed citations

15.

Orange, Jordan S., Narayanaswamy Ramesh, Eileen Remold‐O’Donnell, et al.. (2002). Wiskott–Aldrich syndrome protein is required for NK cell cytotoxicity and colocalizes with actin to NK cell-activating immunologic synapses. Proceedings of the National Academy of Sciences. 99(17). 11351–11356. 222 indexed citations

16.

Koopman, Louise A., Willem E. Corver, Arno R. van der Slik, Marius J. Giphart, & Gert Jan Fleuren. (2000). Multiple Genetic Alterations Cause Frequent and Heterogeneous Human Histocompatibility Leukocyte Antigen Class I Loss in Cervical Cancer. The Journal of Experimental Medicine. 191(6). 961–976. 218 indexed citations

17.

Corver, Willem E., Louise A. Koopman, Arend Mulder, Cees J. Cornelisse, & Gert Jan Fleuren. (2000). Distinction between HLA class I-positive and -negative cervical tumor subpopulations by multiparameter DNA flow cytometry. Cytometry. 41(1). 73–80. 12 indexed citations

18.

Corver, Willem E., et al.. (2000). Four-color multiparameter DNA flow cytometric method to study phenotypic intratumor heterogeneity in cervical cancer. Cytometry. 39(2). 96–107. 24 indexed citations

19.

Koopman, Louise A., Arno R. van der Slik, M. J. Giphart, & G.J. Fleuren. (1999). Human Leukocyte Antigen Class I Gene Mutations in Cervical Cancer. JNCI Journal of the National Cancer Institute. 91(19). 1669–1677. 48 indexed citations

20.

Koopman, Louise A., Arend Mulder, Willem E. Corver, et al.. (1998). HLA class I phenotype and genotype alterations in cervical carcinomas and derivative cell lines. Tissue Antigens. 51(6). 623–636. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact